{"id":"levocarnitine","rwe":[],"_fda":{"id":"2a4543d7-2fcf-548c-e063-6394a90af66e","set_id":"05ab18c1-fb01-48fa-8f05-0200bb8a5edf","openfda":{"nui":["M0003493","N0000175903"],"upc":["0352817830043"],"unii":["0G389FZZ9M"],"route":["ORAL"],"rxcui":["315134"],"spl_id":["2a4543d7-2fcf-548c-e063-6394a90af66e"],"brand_name":["Levocarnitine"],"spl_set_id":["05ab18c1-fb01-48fa-8f05-0200bb8a5edf"],"package_ndc":["52817-830-04"],"product_ndc":["52817-830"],"generic_name":["LEVOCARNITINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Carnitine [CS]"],"substance_name":["LEVOCARNITINE"],"pharm_class_epc":["Carnitine Analog [EPC]"],"manufacturer_name":["TRUPHARMA, LLC"],"application_number":["ANDA212533"],"is_original_packager":[true]},"version":"2","warnings":["WARNINGS Hypersensitivity Reactions Serious hypersensitivity reactions, including rash, urticaria, and facial edema have been reported with oral levocarnitine. Other serious hypersensitivity reactions, including anaphylaxis, laryngeal edema, and bronchospasm have been reported following intravenous levocarnitine administration, mostly in patients with end-stage renal disease undergoing dialysis. Discontinue use of levocarnitine and instruct patients to seek medical attention if they experience symptoms suggestive of a hypersensitivity reaction."],"pregnancy":["Pregnancy Reproductive studies have been performed in rats and rabbits at doses up to 3.8 times the human dose on the basis of surface area and have revealed no evidence of impaired fertility or harm to the fetus due to levocarnitine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed."],"overdosage":["OVERDOSAGE There have been no reports of toxicity from levocarnitine overdosage. Levocarnitine is easily removed from plasma by dialysis. The intravenous LD 50 of levocarnitine in rats is 5.4 g/kg and the oral LD 50 of levocarnitine in mice is 19.2 g/kg. Large doses of levocarnitine may cause diarrhea."],"references":["REFERENCES Bohmer, T., Rydning, A. and Solberg, H.E. 1974. Carnitine levels in human serum in health and disease. Clin. Chim. Acta 57:55-61. Brooks, H., Goldberg, L., Holland, R. et al . 1977. Carnitine-induced effects on cardiac and peripheral hemodynamics. J. Clin. Pharmacol . 17:561-568. Christiansen, R., Bremer, J. 1976. Active transport of butyrobetaine and carnitine into isolated liver cells. Biochim. Biophys . Acta 448:562-577. Lindstedt, S. and Lindstedt, G. 1961. Distribution and excretion of carnitine in the rat. Acta Chem. Scand . 15:701-702. Rebouche, C.J. and Engel, A.G. 1983. Carnitine metabolism and deficiency syndromes. Mayo Clin. Proc. 58:533-540. Rebouche, C.J. and Paulson, D.J. 1986. Carnitine metabolism and function in humans. Ann. Rev. Nutr. 6:41-66. Scriver, C.R., Beaudet, A.L., Sly, W.S. and Valle, D. 1989. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill. Schaub, J., Van Hoof, F. and Vis, H.L. 1991. Inborn Errors of Metabolism . New York: Raven Press. Marzo, A., Arrigoni Martelli, E., Mancinelli, A., Cardace, G., Corbelletta, C., Bassani, E. and Solbiati, M. 1991. Protein binding of L-carnitine family components. Eur. J. Drug Met. Pharmacokin., Special Issue III: 364-368. Rebouche, C.J. 1991. Quantitative estimation of absorption and degradation of a carnitine supplement by human adults. Metabolism 40:1305-1310. Manufactured by: Saptalis Pharmaceuticals, LLC Hauppauge, NY 11788 Distributed by: TruPharma, LLC Tampa, FL 33609 MADE IN USA 12/21-R1"],"description":["DESCRIPTION Levocarnitine is a carrier molecule in the transport of long-chain fatty acids across the inner mitochondrial membrane. The chemical name of levocarnitine is 3-carboxy-2(R)-hydroxy-N,N,N-trimethyl-1-propanaminium, inner salt. Levocarnitine, USP is a white crystalline, hygroscopic powder. It is freely soluble in water, soluble in warm alcohol, and practically insoluble in acetone. The specific rotation of levocarnitine is between -29° and -32°. Its chemical structure is: Molecular formula: C 7 H 15 NO 3 Molecular weight: 161.20 Each 118 mL container of levocarnitine oral solution, USP contains 1 g of levocarnitine, USP/10 mL. Also contains: artificial cherry flavor, ethyl alcohol (0.0094%), malic acid, purified water, sucrose. Methylparaben and propylparaben are added as preservatives. The pH is between 4.0 to 6.0. chemical structure"],"precautions":["PRECAUTIONS General Levocarnitine oral solution is for oral/internal use only. Not for parenteral use. Gastrointestinal reactions may result from a too rapid consumption of carnitine. Levocarnitine oral solution may be consumed alone, or dissolved in drinks or other liquid foods to reduce taste fatigue. They should be consumed slowly and doses should be spaced evenly throughout the day to maximize tolerance. The safety and efficacy of oral levocarnitine have not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral levocarnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine. Drug Interactions Reports of INR increase with the use of warfarin have been observed. It is recommended that INR levels be monitored in patients on warfarin therapy after the initiation of treatment with levocarnitine or after dose adjustments. Carcinogenesis, Mutagenesis, Impairment of Fertility Mutagenicity tests performed in Salmonella typhimurium, Saccharomyces cerevisiae, and Schizosaccharomyces pombe indicate that levocarnitine is not mutagenic. No long-term animal studies have been performed to evaluate the carcinogenic potential of levocarnitine. Pregnancy Reproductive studies have been performed in rats and rabbits at doses up to 3.8 times the human dose on the basis of surface area and have revealed no evidence of impaired fertility or harm to the fetus due to levocarnitine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers Levocarnitine supplementation in nursing mothers has not been specifically studied. Studies in dairy cows indicate that the concentration of levocarnitine in milk is increased following exogenous administration of levocarnitine. In nursing mothers receiving levocarnitine, any risks to the child of excess carnitine intake need to be weighed against the benefits of levocarnitine supplementation to the mother. Consideration may be given to discontinuation of nursing or of levocarnitine treatment. Pediatric Use See DOSAGE AND ADMINISTRATION ."],"how_supplied":["HOW SUPPLIED Levocarnitine oral solution, USP is a clear colorless solution with cherry flavor, supplied in 118 mL (4 fl. oz.) plastic containers (NDC 52817-830-04). Store at controlled room temperature 15º to 30 ºC (59º to 86º F) [see USP]."],"pediatric_use":["Pediatric Use See DOSAGE AND ADMINISTRATION ."],"effective_time":"20241227","nursing_mothers":["Nursing Mothers Levocarnitine supplementation in nursing mothers has not been specifically studied. Studies in dairy cows indicate that the concentration of levocarnitine in milk is increased following exogenous administration of levocarnitine. In nursing mothers receiving levocarnitine, any risks to the child of excess carnitine intake need to be weighed against the benefits of levocarnitine supplementation to the mother. Consideration may be given to discontinuation of nursing or of levocarnitine treatment."],"pharmacokinetics":["Pharmacokinetics In a relative bioavailability study in 15 healthy adult male volunteers, levocarnitine tablets were found to be bio-equivalent to levocarnitine oral solution. Following 4 days of dosing with 6 tablets of levocarnitine 330 mg b.i.d. or 2 g of levocarnitine oral solution b.i.d., the maximum plasma concentration (C max ) was about 80 µmol/L and the time to maximum plasma concentration (T max ) occurred at 3.3 hours. The plasma concentration profiles of levocarnitine after a slow 3-minute intravenous bolus dose of 20 mg/kg of levocarnitine were described by a two-compartment model. Following a single i.v. administration, approximately 76% of the levocarnitine dose was excreted in the urine during the 0-24h interval. Using plasma concentrations uncorrected for endogenous levocarnitine, the mean distribution half-life was 0.585 hours and the mean apparent terminal elimination half-life was 17.4 hours. The absolute bioavailability of levocarnitine from the two oral formulations of levocarnitine, calculated after correction for circulating endogenous plasma concentrations of levocarnitine, was 15.1 ± 5.3% for levocarnitine tablets and 15.9 ± 4.9% for levocarnitine oral solution. Total body clearance of levocarnitine (Dose/AUC including endogenous baseline concentrations) was a mean of 4.00 L/h. Levocarnitine was not bound to plasma protein or albumin when tested at any concentration or with any species including the human. 9"],"adverse_reactions":["ADVERSE REACTIONS The following adverse reactions associated with the use of oral formulations of levocarnitine were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliability, or to establish a causal relationship to drug exposure. Gastrointestinal Reactions : Various mild gastrointestinal complaints have been reported during the long-term administration of oral L- or D,L-carnitine; these include transient nausea and vomiting, abdominal cramps, and diarrhea. Gastrointestinal adverse reactions with levocarnitine oral solution dissolved in liquids might be avoided by a slow consumption of the solution or by a greater dilution. Decreasing the dosage often diminishes or eliminates drug-related patient body odor or gastrointestinal symptoms when present. Tolerance should be monitored very closely during the first week of administration and after any dosage increases. Musculoskeletal Reactions : Mild myasthenia has been described only in uremic patients receiving D,L-carnitine. Neurologic Reactions : Seizures have been reported to occur in patients with or without pre-existing seizure activity receiving either oral or intravenous levocarnitine. In patients with pre-existing seizure activity, an increase in seizure frequency and/or severity has been reported. Hypersensitivity Reactions : Rash, urticaria, and facial edema have been reported with oral levocarnitine (see WARNINGS ). To report SUSPECTED ADVERSE REACTIONS, contact Saptalis Pharmaceuticals, LLC at 1-833-727-8254 or FDA at 1­-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS None known."],"drug_interactions":["Drug Interactions Reports of INR increase with the use of warfarin have been observed. It is recommended that INR levels be monitored in patients on warfarin therapy after the initiation of treatment with levocarnitine or after dose adjustments."],"general_precautions":["General Levocarnitine oral solution is for oral/internal use only. Not for parenteral use. Gastrointestinal reactions may result from a too rapid consumption of carnitine. Levocarnitine oral solution may be consumed alone, or dissolved in drinks or other liquid foods to reduce taste fatigue. They should be consumed slowly and doses should be spaced evenly throughout the day to maximize tolerance. The safety and efficacy of oral levocarnitine have not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral levocarnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Levocarnitine is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering a substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain. In skeletal and cardiac muscle, fatty acids are the main substrate for energy production. Primary systemic carnitine deficiency is characterized by low concentrations of levocarnitine in plasma, RBC, and/or tissues. It has not been possible to determine which symptoms are due to carnitine deficiency and which are due to an underlying organic acidemia, as symptoms of both abnormalities may be expected to improve with levocarnitine. The literature reports that carnitine can promote the excretion of excess organic or fatty acids in patients with defects in fatty acid metabolism and/or specific organic acidopathies that bioaccumulate acyl-CoA esters. 1-6 Secondary carnitine deficiency can be a consequence of inborn errors of metabolism. Levocarnitine may alleviate the metabolic abnormalities of patients with inborn errors that result in accumulation of toxic organic acids. Conditions for which this effect has been demonstrated are: glutaric aciduria II, methyl malonic aciduria, propionic acidemia, and medium chain fatty acyl-CoA dehydrogenase deficiency. 7,8 Autointoxication occurs in these patients due to the accumulation of acyl-CoA compounds that disrupt intermediary metabolism. The subsequent hydrolysis of the acyl-CoA compound to its free acid results in acidosis which can be life-threatening. Levocarnitine clears the acyl-CoA compound by formation of acylcarnitine, which is quickly excreted. Carnitine deficiency is defined biochemically as abnormally low plasma concentrations of free carnitine, less than 20 µmol/L at one-week post term and may be associated with low tissue and/or urine concentrations. Further, this condition may be associated with a plasma concentration ratio of acylcarnitine/levocarnitine greater than 0.4 or abnormally elevated concentrations of acylcarnitine in the urine. In premature infants and newborns, secondary deficiency is defined as plasma levocarnitine concentrations below age-related normal concentrations."],"indications_and_usage":["INDICATIONS AND USAGE Levocarnitine oral solution is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine oral solution is also indicated for the acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency."],"spl_unclassified_section":["For Oral Use Only. Not for Parenteral Use. Rx only","Metabolism and Excretion In a pharmacokinetic study where five normal adult male volunteers received an oral dose of [ 3 H-methyl]-L-carnitine following 15 days of a high carnitine diet and additional carnitine supplement, 58 to 65% of the administered radioactive dose was recovered in the urine and feces in 5 to 11 days. The maximum concentration of [ 3 H-methyl]-L-carnitine in serum occurred from 2 to 4.5 hours after drug administration. Major metabolites found were trimethylamine N-oxide, primarily in urine (8% to 49% of the administered dose) and [ 3 H]-γ-butyrobetaine, primarily in feces (0.44% to 45% of the administered dose). Urinary excretion of levocarnitine was about 4 to 8% of the dose. Fecal excretion of total carnitine was less than 1% of the administered dose. 10 After attainment of steady state following 4 days of oral administration of levocarnitine tablets (1,980 mg q12h) or oral solution (2,000 mg q12h) to 15 healthy male volunteers, the mean urinary excretion of levocarnitine during a single dosing interval (12h) was about 9% of the orally administered dose (uncorrected for endogenous urinary excretion)."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION For oral use only. Not for parenteral use. Adults: The recommended dosage of levocarnitine is 1 to 3 g/day for a 50 kg subject, which is equivalent to 10 to 30 mL/day of levocarnitine oral solution. Higher doses should be administered only with caution and only where clinical and biochemical considerations make it seem likely that higher doses will be of benefit. Dosage should start at 1 g/day (10 mL/day), and be increased slowly while assessing tolerance and therapeutic response. Monitoring should include periodic blood chemistries, vital signs, plasma carnitine concentrations, and overall clinical condition. Infants and children: The recommended dosage of levocarnitine is 50 to 100 mg/kg/day which is equivalent to 0.5 mL/kg/day levocarnitine oral solution. Higher doses should be administered only with caution and only where clinical and biochemical considerations make it seem likely that higher doses will be of benefit. Dosage should start at 50 mg/kg/day, and be increased slowly to a maximum of 3 g/day (30 mL/day) while assessing tolerance and therapeutic response. Monitoring should include periodic blood chemistries, vital signs, plasma carnitine concentrations, and overall clinical condition. Levocarnitine oral solution may be consumed alone or dissolved in drink or other liquid food. Doses should be spaced evenly throughout the day (every three or four hours) preferably during or following meals and should be consumed slowly in order to maximize tolerance."],"spl_product_data_elements":["Levocarnitine Levocarnitine CHERRY ALCOHOL MALIC ACID WATER SUCROSE METHYLPARABEN PROPYLPARABEN LEVOCARNITINE LEVOCARNITINE"],"package_label_principal_display_panel":["Package/Label Display Panel NDC 52817-830-04 Levocarnitine Oral Solution, USP 1 g/10 mL Rx only 118 mL (4 fl. oz.) Multiple Unit Container 1 g/10 mL-118 mL (4 fl. oz.)"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Mutagenicity tests performed in Salmonella typhimurium, Saccharomyces cerevisiae, and Schizosaccharomyces pombe indicate that levocarnitine is not mutagenic. No long-term animal studies have been performed to evaluate the carcinogenic potential of levocarnitine."]},"tags":[{"label":"Carnitine Analog","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Carnitine O-palmitoyltransferase 1, liver isoform","category":"target"},{"label":"CPT1A","category":"gene"},{"label":"A16AA01","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Topical","category":"route"},{"label":"Oral","category":"route"},{"label":"Injection","category":"form"},{"label":"Liquid","category":"form"},{"label":"Lotion","category":"form"},{"label":"Solution","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Carnitine deficiency","category":"indication"},{"label":"Leadiant Biosci Inc","category":"company"},{"label":"Approved 1980s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"SEIZURE","source":"FDA FAERS","actionTaken":"361 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"254 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"216 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"196 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"183 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"172 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"168 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"163 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"127 reports"},{"date":"","signal":"PRODUCT DOSE OMISSION ISSUE","source":"FDA FAERS","actionTaken":"125 reports"}],"drugInteractions":[{"drug":"warfarin","severity":"major","mechanism":"not specified","management":"monitor INR levels in patients on warfarin therapy after the initiation of treatment with levocarnitine or after dose adjustments","clinicalEffect":"INR increase"}],"commonSideEffects":[{"effect":"Seizures","drugRate":"reported","severity":"unknown"},{"effect":"Nausea","drugRate":"reported","severity":"unknown"},{"effect":"Vomiting","drugRate":"reported","severity":"unknown"},{"effect":"Abdominal cramps","drugRate":"reported","severity":"unknown"},{"effect":"Diarrhea","drugRate":"reported","severity":"unknown"},{"effect":"Myasthenia","drugRate":"reported","severity":"unknown"},{"effect":"Body odor","drugRate":"reported","severity":"unknown"}],"contraindications":["Blood coagulation disorder","Disease of liver","Kidney disease","Low blood pressure","Obstruction of bile duct","Seizure disorder","Vitamin K Deficiency Induced Hypoprothrombinemia"],"specialPopulations":{"Pregnancy":"Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.","Paediatric use":"See DOSAGE AND ADMINISTRATION."}},"trials":[],"aliases":[],"company":"Leadiant Biosci Inc","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.1711/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$62","description":"LEVOCARNITINE 1 G/10 ML SOLN","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=LEVOCARNITINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:35:05.663560+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Levocarnitine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:35:12.744349+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:35:11.325291+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:35:04.779204+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LEVOCARNITINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:35:11.689688+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:01.888030+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:01.888063+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:01.888069+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:35:13.161747+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:20.097496+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1149/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:35:12.388780+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA212533","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:01.888072+00:00"}},"allNames":"carnitor","offLabel":[],"synonyms":["carnitine","(-)-Carnitine","(-)-L-Carnitine","(R)-Carnitine","carniking","carnilean","carnitene","carnivit","l-Carnitine","levocarnitine","levocarnitine hydrochloride","levocarnitine HCl"],"timeline":[{"date":"1985-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from SIGMA TAU to Leadiant Biosci Inc"},{"date":"1985-12-27","type":"positive","source":"DrugCentral","milestone":"FDA approval (Sigma Tau)"},{"date":"1988-04-27","type":"positive","source":"FDA Orange Book","milestone":"Carnitor approved — 1GM/10ML"},{"date":"1992-12-16","type":"positive","source":"FDA Orange Book","milestone":"Carnitor approved — 200MG/ML"},{"date":"2004-08-10","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 4 manufacturers approved"}],"aiSummary":"Carnitor (Levocarnitine) is a carnitine analog developed by SIGMA TAU and currently owned by Leadiant Biosci Inc. It targets the liver isoform of Carnitine O-palmitoyltransferase 1, a key enzyme in fatty acid metabolism. FDA-approved in 1985 for treating carnitine deficiency, Carnitor is a small molecule with a half-life of 5 hours and bioavailability of 15%. The drug is off-patent with 7 generic manufacturers available. Key safety considerations include its potential to cause gastrointestinal side effects and interactions with other medications.","approvals":[{"date":"1985-12-27","orphan":true,"company":"SIGMA TAU","regulator":"FDA"}],"brandName":"Carnitor","ecosystem":[{"indication":"Carnitine deficiency","otherDrugs":[],"globalPrevalence":6160000}],"mechanism":{"target":"Carnitine O-palmitoyltransferase 1, liver isoform","novelty":"First-in-class","targets":[{"gene":"CPT1A","source":"DrugCentral","target":"Carnitine O-palmitoyltransferase 1, liver isoform","protein":"Carnitine O-palmitoyltransferase 1, liver isoform"}],"modality":"Small Molecule","drugClass":"Carnitine Analog [EPC]","explanation":"","oneSentence":"","technicalDetail":"Carnitor (levocarnitine) acts as a substrate for the liver isoform of Carnitine O-palmitoyltransferase 1 (CPT1), facilitating the transport of long-chain fatty acids into the mitochondria for beta-oxidation and energy production."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Carnitine","title":"Carnitine","extract":"Carnitine is a quaternary ammonium compound involved in metabolism in most mammals, plants, and some bacteria. In support of energy metabolism, carnitine transports long-chain fatty acids from the cytosol into mitochondria to be oxidized for free energy production, and also participates in removing products of metabolism from cells. Given its key metabolic roles, carnitine is concentrated in tissues like skeletal and cardiac muscle that metabolize fatty acids as an energy source. Generally individuals, including strict vegetarians, synthesize enough L-carnitine in vivo.","wiki_history":"== History ==\nLevocarnitine was approved by the U.S. Food and Drug Administration as a new molecular entity under the brand name Carnitor on December 27, 1985."},"commercial":{"launchDate":"1985","_launchSource":"DrugCentral (FDA 1985-12-27, SIGMA TAU)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/513","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LEVOCARNITINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LEVOCARNITINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Carnitine","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:18:54.224912","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:35:20.787799+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"glutamine","drugSlug":"glutamine","fdaApproval":"2004-06-10","relationship":"same-class"},{"drugName":"mercaptamine","drugSlug":"mercaptamine","fdaApproval":"1994-08-15","relationship":"same-class"},{"drugName":"carglumic acid","drugSlug":"carglumic-acid","fdaApproval":"2010-03-18","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"betaine","drugSlug":"betaine","fdaApproval":"1996-10-25","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"metreleptin","drugSlug":"metreleptin","fdaApproval":"2014-02-24","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"levocarnitine","indications":{"approved":[{"name":"Carnitine deficiency","source":"DrugCentral","snomedId":421784001,"regulator":"FDA","prevalenceClass":"6-9 / 10 000","globalPrevalence":6160000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (17417720[PMID])"}],"offLabel":[{"name":"Recovery during viral myocarditis","source":"DrugCentral","drugName":"LEVOCARNITINE","evidenceCount":0,"evidenceLevel":"emerging"}],"pipeline":[]},"currentOwner":"Leadiant Biosci Inc","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"glutamine","brandName":"glutamine","genericName":"glutamine","approvalYear":"2004","relationship":"same-class"},{"drugId":"mercaptamine","brandName":"mercaptamine","genericName":"mercaptamine","approvalYear":"1994","relationship":"same-class"},{"drugId":"carglumic-acid","brandName":"carglumic acid","genericName":"carglumic acid","approvalYear":"2010","relationship":"same-class"},{"drugId":"betaine","brandName":"betaine","genericName":"betaine","approvalYear":"1996","relationship":"same-class"},{"drugId":"metreleptin","brandName":"metreleptin","genericName":"metreleptin","approvalYear":"2014","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07492446","phase":"NA","title":"Effects of Carnitine Supplementation on Exercise-Induced Muscle Damage: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Istanbul Sabahattin Zaim University","startDate":"2025-05-09","conditions":["Recovery Methods","Exercise and Recovery","Exercise Fatigue","Carnitine Ingestion","Exercise Ergogenics"],"enrollment":30,"completionDate":"2025-06-05"},{"nctId":"NCT03994471","phase":"PHASE3","title":"Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.","status":"RECRUITING","sponsor":"Iperboreal Pharma Srl","startDate":"2022-12-14","conditions":["End Stage Renal Disease"],"enrollment":170,"completionDate":"2027-04-28"},{"nctId":"NCT01731236","phase":"EARLY_PHASE1","title":"CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2011-02-11","conditions":["Dietary Modification"],"enrollment":100,"completionDate":"2029-12"},{"nctId":"NCT07393360","phase":"NA","title":"Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment","status":"RECRUITING","sponsor":"Pharmanutra S.p.a.","startDate":"2025-12-11","conditions":["Obesity & Overweight"],"enrollment":144,"completionDate":"2026-12"},{"nctId":"NCT07467889","phase":"","title":"Impact of CRRT on Serum Carnitine and Micronutrient Levels","status":"COMPLETED","sponsor":"Gulhane Training and Research Hospital","startDate":"2023-01-01","conditions":["Acute Kidney Injury (Nontraumatic)","Critical Illness"],"enrollment":43,"completionDate":"2025-12-15"},{"nctId":"NCT05602194","phase":"PHASE3","title":"Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-08-14","conditions":["B Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","B Acute Lymphoblastic Leukemia, BCR-ABL1-Like","Lymphoblastic Lymphoma","Mixed Phenotype Acute Leukemia","T Acute Lymphoblastic Leukemia"],"enrollment":440,"completionDate":"2028-12-30"},{"nctId":"NCT04632953","phase":"","title":"Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2021-11-30","conditions":["Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)"],"enrollment":150,"completionDate":"2035-12"},{"nctId":"NCT07437391","phase":"NA","title":"Effect of L-Carnitine Supplementation in Preterm Neonates","status":"RECRUITING","sponsor":"Muhammad Aamir Latif","startDate":"2026-01-01","conditions":["Respiratory Distress Syndrome"],"enrollment":160,"completionDate":"2026-06-30"},{"nctId":"NCT07216001","phase":"PHASE2","title":"Role of Omega-DEK in Childhood Apraxia of Speech","status":"NOT_YET_RECRUITING","sponsor":"Claudia R. Morris","startDate":"2026-05","conditions":["Childhood Apraxia of Speech","Verbal Apraxia","Autism"],"enrollment":34,"completionDate":"2027-12"},{"nctId":"NCT07402759","phase":"PHASE3","title":"Impact of tdrd9 Gene Mutations in the Therapeutic Response to L-carnitine in Oligoasthenozoospermic Men","status":"ACTIVE_NOT_RECRUITING","sponsor":"South Valley University","startDate":"2026-01-01","conditions":["Oligoasthenozoospermia","Male Infertility"],"enrollment":50,"completionDate":"2026-08"},{"nctId":"NCT05767515","phase":"NA","title":"The Effects of Acetyl-L-Carnitine and Myo/Chiro-Inositol in Patients With PCOS","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2023-07-15","conditions":["Infertility, Female","PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries"],"enrollment":120,"completionDate":"2024-03-10"},{"nctId":"NCT06960694","phase":"PHASE2","title":"Effect of L-carnitine on Disease Activity in Patients With Mild to Moderate Knee Osteoarthritis","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2025-06-28","conditions":["Knee Osteoarthritis"],"enrollment":66,"completionDate":"2025-11-19"},{"nctId":"NCT05933200","phase":"PHASE3","title":"A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2023-02-28","conditions":["Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)"],"enrollment":69,"completionDate":"2027-08"},{"nctId":"NCT05980884","phase":"NA","title":"Using Gut Microbial Gbu Gene Testing to Estimate Host TMAO Production Capacity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2023-07-24","conditions":["Gut Dysbiosis for TMAO Production From L-carnitine Consumption"],"enrollment":230,"completionDate":"2026-07-30"},{"nctId":"NCT03773770","phase":"","title":"Expanded Access to Triheptanoin","status":"AVAILABLE","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"","conditions":["Long Chain Fatty Acid Oxidation Disorders"],"enrollment":0,"completionDate":""},{"nctId":"NCT07322575","phase":"NA","title":"Development of Microbial Metabolism Gene Tests for Facilitating Precision Health and Preventive Medicine-Evaluation of TMAO Production in Human Body From High-carnitine Diet by Fecal Gbu Gene Testing","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-01-15","conditions":["Gut Dysbiosis for TMAO Production From Red Meat Consumption"],"enrollment":65,"completionDate":"2026-11-30"},{"nctId":"NCT07303088","phase":"NA","title":"Effects of L-carnitine and Coenzyme Q10 Supplementation on Oxidative Stress in Tunisian Hemodialysis Patients.","status":"COMPLETED","sponsor":"University of Sfax","startDate":"2024-06-17","conditions":["Oxidative Stress Response","Hemodialysis","End Stage Kidney Disease (ESRD)"],"enrollment":52,"completionDate":"2024-11-30"},{"nctId":"NCT07298564","phase":"NA","title":"Effect of Magnesium and Levocarnitine on Metabolic and Clinical Outcomes in Women With Polycystic Ovarian Syndrome (PCOS)","status":"RECRUITING","sponsor":"Behnood Abbasi","startDate":"2026-01-30","conditions":["Polycystic Ovary Syndrome (PCOS)"],"enrollment":84,"completionDate":"2026-11-30"},{"nctId":"NCT07266259","phase":"NA","title":"Effect of Levocarnitine Plus Myoinositol Versus Myoinositol Alone on Hormonal and Insulin Resistance in PCOS Women","status":"RECRUITING","sponsor":"Mst.Sumyara Khatun","startDate":"2025-09-19","conditions":["Polycystic Ovary Syndrome (PCOS)"],"enrollment":72,"completionDate":"2027-03-01"},{"nctId":"NCT07249229","phase":"PHASE2","title":"Oral L-carnitine and Inflammatory and Nutritional Biomarkers in Maintenance Hemodialysis","status":"COMPLETED","sponsor":"Darya Chamani","startDate":"2020-11-30","conditions":["End-stage Renal Disease (ESRD)","Hemodialysis"],"enrollment":50,"completionDate":"2021-03-08"},{"nctId":"NCT04128969","phase":"PHASE2","title":"Causal Mechanisms in Adolescent Arterial Stiffness","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2020-02-01","conditions":["Lipid Disorder","Dyslipidemias","Aortic Stiffness","Insulin Resistance Syndrome","Metabolic Syndrome","Pediatric Obesity"],"enrollment":90,"completionDate":"2026-08-31"},{"nctId":"NCT06158659","phase":"NA","title":"Improved Immunology Outcomes Associated With Lactoferrin Fortified With HMO in Infant Formula","status":"COMPLETED","sponsor":"Heilongjiang Feihe Dairy Co. Ltd.","startDate":"2023-11-14","conditions":["Flu","Cold"],"enrollment":240,"completionDate":"2025-04-03"},{"nctId":"NCT06159088","phase":"NA","title":"Improved Gut Health Outcomes Associated With Probiotics Fortified With Hydrolyzed Whey Protein in Infant Formula","status":"COMPLETED","sponsor":"Heilongjiang Feihe Dairy Co. Ltd.","startDate":"2023-11-14","conditions":["Gut Health","Gastrointestinal Diseases"],"enrollment":240,"completionDate":"2025-04-03"},{"nctId":"NCT06146387","phase":"NA","title":"Improved Cognitive Outcomes Associated With Feihe HMO With DHA/ARA in Infant Formula","status":"COMPLETED","sponsor":"Heilongjiang Feihe Dairy Co. Ltd.","startDate":"2023-11-14","conditions":["Cognitive Change"],"enrollment":240,"completionDate":"2025-04-03"},{"nctId":"NCT03953703","phase":"PHASE2","title":"Levocarnitine for Dry Eye in Sjogren's Syndrome","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2021-11-17","conditions":["Sjogren's Syndrome","Keratoconjunctivitis Sicca"],"enrollment":15,"completionDate":"2025-09-19"},{"nctId":"NCT02016430","phase":"NA","title":"Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2014-04-04","conditions":["Dietary Modification","Cardiovascular Risk Factor"],"enrollment":170,"completionDate":"2026-12"},{"nctId":"NCT05251207","phase":"NA","title":"Plasma Trimethylamine N-oxide Elevation Induced by L-carnitine Supplementation and Insulin Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Poznan University of Physical Education","startDate":"2022-02-07","conditions":["Insulin Resistance"],"enrollment":40,"completionDate":"2027-05-31"},{"nctId":"NCT06137833","phase":"NA","title":"Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy","status":"RECRUITING","sponsor":"Pharmanutra S.p.a.","startDate":"2023-11-27","conditions":["Fatigue","Breast Cancer"],"enrollment":92,"completionDate":"2025-12-31"},{"nctId":"NCT07201714","phase":"EARLY_PHASE1","title":"Oral Carnitine in Heart Failure Patients","status":"NOT_YET_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2025-12-01","conditions":["Heart Failure","Carnitine Deficiency"],"enrollment":20,"completionDate":"2026-12-31"},{"nctId":"NCT04908397","phase":"PHASE1","title":"Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2021-09-29","conditions":["Pulmonary Arterial Hypertension","Familial Primary Pulmonary Hypertension","Primary Pulmonary Hypertension","Lung Diseases","Carnitine Nutritional Deficiency"],"enrollment":10,"completionDate":"2023-06-30"},{"nctId":"NCT06126315","phase":"PHASE2,PHASE3","title":"Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS","status":"RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2025-03-26","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":246,"completionDate":"2027-09"},{"nctId":"NCT07160452","phase":"PHASE4","title":"Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia","status":"NOT_YET_RECRUITING","sponsor":"Shaikh Zayed Hospital, Lahore","startDate":"2025-09-15","conditions":["Anemia","Kidney Failure","End-Stage Renal Disease","Renal Dialysis"],"enrollment":94,"completionDate":"2026-03-15"},{"nctId":"NCT03564678","phase":"PHASE2","title":"Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-17","conditions":["Acute Lymphoblastic Leukemia","Hyperbilirubinemia"],"enrollment":10,"completionDate":"2024-10-15"},{"nctId":"NCT02664753","phase":"PHASE3","title":"L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2018-03-05","conditions":["Severe Sepsis","Shock, Septic","Acute Kidney Injury"],"enrollment":254,"completionDate":"2024-12-04"},{"nctId":"NCT06573229","phase":"NA","title":"LIver FRAilty Management IN Cirrhosis (LIFRAMIN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-08-02","conditions":["Sarcopenia","Cirrhosis, Liver","Malnutrition; Protein"],"enrollment":30,"completionDate":"2025-10-30"},{"nctId":"NCT07108777","phase":"PHASE2","title":"L-Carnitine Protective Effect in Nephrotoxicity","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-08-10","conditions":["Nephrotoxicity"],"enrollment":46,"completionDate":"2026-11-01"},{"nctId":"NCT06845046","phase":"NA","title":"A Study to Improve Skeletal Muscle in Veterans With HIV","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-07-15","conditions":["HIV","Obesity"],"enrollment":70,"completionDate":"2029-06-29"},{"nctId":"NCT06689501","phase":"NA","title":"12-Week Trial Investigating L-carnitine Tartrate, Dihydrocapsiate and Protein Yeast Hydrolysate on Energy Intake and Expenditure in Overweight Adults","status":"COMPLETED","sponsor":"Société des Produits Nestlé (SPN)","startDate":"2024-10-30","conditions":["Overweight and Obesity"],"enrollment":44,"completionDate":"2025-06-26"},{"nctId":"NCT06564909","phase":"PHASE2","title":"Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-06-01","conditions":["Reperfusion Injury, Myocardial","Myocardial Infarction"],"enrollment":76,"completionDate":"2026-03"},{"nctId":"NCT07035444","phase":"NA","title":"Enteral Nutrition With L-Carnitine for Cachexia in Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2025-06-30","conditions":["Non-Small Cell Lung Cancer","Cachexia"],"enrollment":126,"completionDate":"2026-12-31"},{"nctId":"NCT05355311","phase":"PHASE1","title":"Enhancing the Effects of Alcohol Treatment With L-Carnitine","status":"COMPLETED","sponsor":"Brown University","startDate":"2024-09-27","conditions":["Alcohol Use Disorder"],"enrollment":24,"completionDate":"2025-05-31"},{"nctId":"NCT06518343","phase":"NA","title":"Trimethylamine N-oxide Effects of a Pomegranate Supplement Simultaneously With Carnitine (TESSA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Quadram Institute Bioscience","startDate":"2024-08-12","conditions":["Healthy"],"enrollment":39,"completionDate":"2027-05-31"},{"nctId":"NCT07016867","phase":"NA","title":"Medical Treatment Alone Versus Varicocelectomy Versus Varicocelectomy and Medical Treatment","status":"RECRUITING","sponsor":"South Valley University","startDate":"2024-09-01","conditions":["Teratozoospermia"],"enrollment":126,"completionDate":"2025-08-31"},{"nctId":"NCT04946123","phase":"NA","title":"Hyperthyroidism: Methimazole Plus L-carnitine and Selenium","status":"COMPLETED","sponsor":"Lo.Li.Pharma s.r.l","startDate":"2021-07-05","conditions":["Hyperthyroidism"],"enrollment":60,"completionDate":"2025-06-04"},{"nctId":"NCT04913805","phase":"PHASE2","title":"Matching Perfusion and Metabolic Activity in HFpEF","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-10-11","conditions":["Heart Failure With Preserved Ejection Fraction"],"enrollment":53,"completionDate":"2027-05-01"},{"nctId":"NCT05681806","phase":"NA","title":"Assessment of the Efficacy of Carnipure® AAS on Body Composition, Muscle Thickness, and Strength Adaptations in Healthy Men","status":"COMPLETED","sponsor":"Applied Science & Performance Institute","startDate":"2023-02-23","conditions":["Muscle Hypotrophy"],"enrollment":44,"completionDate":"2025-05-12"},{"nctId":"NCT03994874","phase":"PHASE1,PHASE2","title":"Peritoneal Ultrafiltration in Cardio Renal Syndrome.","status":"RECRUITING","sponsor":"Iperboreal Pharma Srl","startDate":"2025-04-16","conditions":["Congestive Heart Failure"],"enrollment":84,"completionDate":"2027-06"},{"nctId":"NCT06849115","phase":"PHASE4","title":"Effects of L-Carnitine in Amyotrophic Lateral Sclerosis Patients With CHCHD10 Mutations","status":"COMPLETED","sponsor":"ChaodongWang","startDate":"2024-07-18","conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"enrollment":4,"completionDate":"2025-02-13"},{"nctId":"NCT06901323","phase":"PHASE4","title":"Effect of L-carnitine Supplementation on Phenylalanine and Brain-derived Neurotrophic Factor Levels in Infants and Children With Phenylketonuria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mansoura University","startDate":"2025-02-01","conditions":["Phenylketonuria"],"enrollment":176,"completionDate":"2026-08-01"},{"nctId":"NCT06718426","phase":"NA","title":"Evaluation of Fertitonex Effects on Semen Parameters in Clinical Varicocele Patient.","status":"RECRUITING","sponsor":"Menoufia University","startDate":"2024-12-01","conditions":["Varicocele"],"enrollment":110,"completionDate":"2026-02-01"},{"nctId":"NCT04284917","phase":"NA","title":"Long-term Efficacy of Carglumic Acid in Organic Acidemia.","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2019-11-28","conditions":["Propionic Acidemia (PA) , Methylmalonic Acidemia (MMA)"],"enrollment":3,"completionDate":"2025-03-11"},{"nctId":"NCT00227266","phase":"PHASE2","title":"Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy","status":"COMPLETED","sponsor":"University of Utah","startDate":"2005-09","conditions":["Spinal Muscular Atrophy"],"enrollment":94,"completionDate":"2007-11"},{"nctId":"NCT04573153","phase":"PHASE2,PHASE3","title":"Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients","status":"TERMINATED","sponsor":"ScandiBio Therapeutics AB","startDate":"2020-09-21","conditions":["COVID-19"],"enrollment":100,"completionDate":"2022-05-05"},{"nctId":"NCT04330326","phase":"PHASE2","title":"Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"ScandiBio Therapeutics AB","startDate":"2019-07-20","conditions":["Non-alcoholic Fatty Liver Disease (NAFLD)"],"enrollment":32,"completionDate":"2022-05-06"},{"nctId":"NCT06023082","phase":"NA","title":"A Single-Group Study to Examine the Efficacy of a Gut Health Supplement to Increase Metabolism, Improve Gut Health, and Support Weight Management","status":"COMPLETED","sponsor":"Gut Health, UAB","startDate":"2023-07-26","conditions":["Gut Health","Metabolism","Weight Loss","Energy"],"enrollment":120,"completionDate":"2023-11-26"},{"nctId":"NCT06753565","phase":"PHASE2","title":"L-carnitine Supplementation in Rheumatoid Arthritis Patients","status":"RECRUITING","sponsor":"German University in Cairo","startDate":"2024-12-31","conditions":["Rheumatoid Arthritis (RA)"],"enrollment":60,"completionDate":"2025-06"},{"nctId":"NCT04086212","phase":"PHASE2","title":"Ultrafiltration Efficacy of a PD Solution Containing Icodextrin-Xylitol-Carnitine","status":"WITHDRAWN","sponsor":"Iperboreal Pharma Srl","startDate":"2019-10-02","conditions":["End Stage Renal Disease (ESRD)"],"enrollment":0,"completionDate":"2023-04"},{"nctId":"NCT05952349","phase":"PHASE2","title":"Effect of Metformin and Combination of Olive Oil Plus Nutritional Supplements on Inflammatory Markers IL-6 and IL-8 in PCOS.","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2023-07-01","conditions":["PCO"],"enrollment":88,"completionDate":"2024-04-01"},{"nctId":"NCT06247813","phase":"PHASE2","title":"Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain","status":"RECRUITING","sponsor":"Ethos Research & Development","startDate":"2024-02-08","conditions":["Chronic Pain"],"enrollment":75,"completionDate":"2025-07-30"},{"nctId":"NCT05501899","phase":"EARLY_PHASE1","title":"Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Children's Hospital of Orange County","startDate":"2023-03-03","conditions":["Acute Lymphoblastic Leukemia","Hepatotoxicity"],"enrollment":20,"completionDate":"2024-12-31"},{"nctId":"NCT05817799","phase":"PHASE2,PHASE3","title":"Impact of Hemodialysis on Plasma Carnitine Levels in Patients With End Stage Renal Disease","status":"COMPLETED","sponsor":"Bahria University","startDate":"2023-01-01","conditions":["Hemodialysis Complication"],"enrollment":83,"completionDate":"2023-07-10"},{"nctId":"NCT05673239","phase":"PHASE4","title":"Effects of L-carnitine Therapy on the Heart of Maintenance Hemodialysis Patients","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Zhejiang Chinese Medical University","startDate":"2023-01-15","conditions":["Renal Dialysis"],"enrollment":1008,"completionDate":"2024-06-30"},{"nctId":"NCT06068140","phase":"","title":"Evaluation of the Effectiveness of the Complex of Carnitine Orotate and Biphenyl Dimethyl Dicarboxylate in the Adjuvant Therapy of Chronic Hepatitis D in Real Clinical Practice: a Prospective Cohort Study","status":"WITHDRAWN","sponsor":"Kazakh Association of Internal Medicine Specialists","startDate":"2023-12","conditions":["Chronic Viral Hepatitis B With Delta-Agent"],"enrollment":0,"completionDate":"2025-06"},{"nctId":"NCT06342856","phase":"EARLY_PHASE1","title":"Evaluation of Treatment With Coenzyme Q10 and L-Carnitine on Semen Parameters in Infertile Men With Idiopathic Oligoasthenoteratospermia","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-06-15","conditions":["Infertility Unexplained","Oligospermia"],"enrollment":120,"completionDate":"2024-07-01"},{"nctId":"NCT05083637","phase":"NA","title":"L-Carnitine Supplementation, Rate of Weight Gain and EED in Children With SAM","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2021-10-19","conditions":["Malnutrition"],"enrollment":98,"completionDate":"2023-03-30"},{"nctId":"NCT05284487","phase":"NA","title":"Clinical Trial to Evaluate Safety and Efficacy of Jalosome® Soothing Gel.","status":"UNKNOWN","sponsor":"Welcare Industries SpA","startDate":"2023-03-27","conditions":["Radiation-induced Dermatitis"],"enrollment":57,"completionDate":"2024-03"},{"nctId":"NCT05653895","phase":"NA","title":"Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2022-12-07","conditions":["PCOS"],"enrollment":120,"completionDate":"2024-02-07"},{"nctId":"NCT06255873","phase":"NA","title":"Effects of L-Carnitine on Gastric Emptying in Children With Drug Resistant Epilepsy on Ketogenic Diet","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-01-20","conditions":["Ketogenic Diet"],"enrollment":30,"completionDate":"2023-11-15"},{"nctId":"NCT06256276","phase":"NA","title":"Nutritional Therapy for Autonomic Dysfunction in Elderly Heart Failure Patients","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2016-07-26","conditions":["Heart Failure"],"enrollment":21,"completionDate":"2018-02-01"},{"nctId":"NCT04602325","phase":"","title":"Systemic Biomarkers of Brain Injury From Hyperammonemia","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2020-07-09","conditions":["Urea Cycle Disorder","Organic Acidemia","Maple Syrup Urine Disease","Glutaric Acidemia I","Fatty Acid Oxidation Disorder","Hypoxic-Ischemic Encephalopathy"],"enrollment":24,"completionDate":"2027-05"},{"nctId":"NCT06233890","phase":"","title":"The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Imperial College Healthcare NHS Trust","startDate":"2023-05-12","conditions":["Chronic Myeloid Leukemia","Chronic Myeloid Leukemia, Chronic Phase","Fatigue","Sleep Disturbance"],"enrollment":50,"completionDate":"2026-05-12"},{"nctId":"NCT06198803","phase":"EARLY_PHASE1","title":"The Effect of Carnitine Supplementation on Cardiac Function and Lipid Profile in Patients With Drug Resistant Epilepsy on Ketogenic Diet","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-01-03","conditions":["l Carnitine With Ketogenic Diet"],"enrollment":52,"completionDate":"2024-07"},{"nctId":"NCT06175260","phase":"","title":"Investigation on the Efficacy of Oral Carnitine Challenge Test Based on a Gut Microbiota Functional Test","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2019-06-05","conditions":["Dysbiosis","Healthy"],"enrollment":91,"completionDate":"2022-06-30"},{"nctId":"NCT02838732","phase":"NA","title":"Investigation on the Effect of Carnitine Supplement on Gut Microbiota and TMAO Production Capacity","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2016-05-18","conditions":["Dietary Exposure"],"enrollment":56,"completionDate":"2019-10-07"},{"nctId":"NCT03781011","phase":"NA","title":"Oral Carnitine Challenge Test Guides Personalized Nutrition for CV Patients","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2018-10-19","conditions":["Dietary Modification","Cardiovascular Diseases"],"enrollment":50,"completionDate":"2020-10-19"},{"nctId":"NCT06152991","phase":"PHASE3","title":"Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy","status":"ENROLLING_BY_INVITATION","sponsor":"Yoon Jun Kim","startDate":"2023-09-25","conditions":["Non-Alcoholic Fatty Liver Disease"],"enrollment":196,"completionDate":"2027-02-26"},{"nctId":"NCT06122012","phase":"NA","title":"To Evaluate the Efficacy and Safety of HSK16149 With L-carnitine in Diabetic Peripheral Neuralgia Patients in China","status":"UNKNOWN","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2023-05-01","conditions":["Diabetic Peripheral Neuropathic Pain"],"enrollment":136,"completionDate":"2024-05"},{"nctId":"NCT05483621","phase":"PHASE1","title":"Hormonal Stimulation of Spermatogenesis","status":"COMPLETED","sponsor":"Egymedicalpedia","startDate":"2021-03-01","conditions":["Azoospermia, Nonobstructive"],"enrollment":100,"completionDate":"2022-03-01"},{"nctId":"NCT06078722","phase":"","title":"Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study","status":"UNKNOWN","sponsor":"Kazakh Association of Internal Medicine Specialists","startDate":"2023-02-08","conditions":["Metabolic-associated Fatty Liver Disease (MAFLD)"],"enrollment":264,"completionDate":"2025-02-08"},{"nctId":"NCT06042738","phase":"NA","title":"Investigation of The Effectiveness of Antioxidant Therapy in Oligoasthenoteratozoospermic Infertile Men","status":"COMPLETED","sponsor":"Ondokuz Mayıs University","startDate":"2021-03-01","conditions":["Male Infertility"],"enrollment":48,"completionDate":"2021-11-01"},{"nctId":"NCT06019858","phase":"NA","title":"A Clinical Trial to Assess the Effects of a Vitamin Shot on Energy Levels","status":"COMPLETED","sponsor":"Vitamin Energy®","startDate":"2023-06-21","conditions":["Energy","Fatigue","Mood","Weight Loss","Cognition"],"enrollment":30,"completionDate":"2023-07-20"},{"nctId":"NCT02214160","phase":"PHASE2","title":"Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2014-12-09","conditions":["Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency","Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency","Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency","Trifunctional Protein (TFP) Deficiency","Carnitine-acylcarnitine Translocase (CACT) Deficiency"],"enrollment":94,"completionDate":"2020-12-03"},{"nctId":"NCT05948124","phase":"EARLY_PHASE1","title":"Carnitine Supplementation in Pediatric Hemodialysis Patients","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-08-01","conditions":["Carnitine Deficiency Due to Hemodialysis"],"enrollment":40,"completionDate":"2024-03-01"},{"nctId":"NCT00091169","phase":"PHASE3","title":"Levocarnitine in Treating Fatigue in Cancer Patients","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2005-12-16","conditions":["Fatigue","Unspecified Adult Solid Tumor, Protocol Specific"],"enrollment":376,"completionDate":"2011-05"},{"nctId":"NCT05115734","phase":"","title":"Acylcarnitine Profile After Intensive Care","status":"UNKNOWN","sponsor":"University of Liege","startDate":"2021-11-03","conditions":["Critical Care","Carnitine Metabolism Disturbances"],"enrollment":100,"completionDate":"2026-01-01"},{"nctId":"NCT04672720","phase":"NA","title":"L-carnitine and COH in PCOS Women Undergoing IVF/ICSI Cycles","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2020-03-01","conditions":["Polycystic Ovary Syndrome"],"enrollment":110,"completionDate":"2023-02-28"},{"nctId":"NCT05905692","phase":"PHASE3","title":"Evaluation of the Impact of L- Carnitine in Intradialytic Hypotension in Pediatric Patients on Regular Hemodialysis","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-05-30","conditions":["Intradialytic Hypotension"],"enrollment":50,"completionDate":"2023-12-30"},{"nctId":"NCT02804828","phase":"NA","title":"Mitochondrial Cocktail for Gulf War Illness","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2021-04-09","conditions":["Gulf War Syndrome","Persian Gulf Syndrome","Mitochondrial Disorders"],"enrollment":15,"completionDate":"2023-04-03"},{"nctId":"NCT05792527","phase":"PHASE3","title":"L-carnitine in Modulating Pain and Inflammation in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-03-05","conditions":["Rheumatoid Arthritis"],"enrollment":46,"completionDate":"2026-03-05"},{"nctId":"NCT01783041","phase":"PHASE2,PHASE3","title":"Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2013-01","conditions":["Prematurity","Neurodevelopmental Disorder","Carnitine Deficiency"],"enrollment":144,"completionDate":"2021-12-28"},{"nctId":"NCT04001036","phase":"PHASE2","title":"Efficacy and Safety Assessments of a Peritoneal Dialysis Solution Containing Glucose, Xylitol, and L-Carnitine in CAPD","status":"TERMINATED","sponsor":"Iperboreal Pharma Srl","startDate":"2019-09-01","conditions":["End Stage Renal Disease"],"enrollment":11,"completionDate":"2022-08-30"},{"nctId":"NCT02792088","phase":"PHASE3","title":"Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2015-07","conditions":["Chronic Hepatitis B"],"enrollment":146,"completionDate":"2020-02"},{"nctId":"NCT03513835","phase":"","title":"Diagnostic Screening Tests and Potential Biomarkers in Mitochondrial Myopathies","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2018-01-01","conditions":["Mitochondrial Myopathies","Healthy Controls"],"enrollment":50,"completionDate":"2019-01-01"},{"nctId":"NCT05647707","phase":"PHASE2","title":"The Efficacy of L-Carnitine in the Management of Acute Carbon Monoxide Poisoning","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-12-15","conditions":["Carbon Monoxide Poisoning"],"enrollment":72,"completionDate":"2023-08-01"},{"nctId":"NCT05632094","phase":"PHASE2","title":"The Efficacy of L-Carnitine in the Management of Acute Clozapine Intoxication","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2023-06","conditions":["Clozapine Poisoning"],"enrollment":40,"completionDate":"2024-12"},{"nctId":"NCT05632549","phase":"PHASE3","title":"The Possible Efficacy and Safety of L-carnitine and Biotin as Adjunctive Therapies in Children With Moderate Persistent Asthma","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-08-08","conditions":["Moderate Persistent Asthma"],"enrollment":66,"completionDate":"2024-08-08"},{"nctId":"NCT05616000","phase":"PHASE2","title":"Comparison of Acetyl- L- Carnitine& Folic Acid Versus Coenzyme Q10& Folic Acid on Semen& Hormonal Parameters& Semen Oxidative Status in Patients of Primary Infertility. A Double Blind Randomized Clinical Trial","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2022-08-06","conditions":["Infertility"],"enrollment":86,"completionDate":"2022-11-29"},{"nctId":"NCT04812106","phase":"","title":"Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program","status":"TERMINATED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2022-07-25","conditions":["Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)"],"enrollment":8,"completionDate":"2022-10-27"},{"nctId":"NCT05601479","phase":"PHASE2","title":"Preventive Effect of Acetyl-L-carnitine on Oxaliplatin-induced Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-11-01","conditions":["Acetylcarnitine","Chemotherapy-induced Peripheral Neuropathy"],"enrollment":100,"completionDate":"2024-12-31"},{"nctId":"NCT05584956","phase":"PHASE3","title":"Clinical Study to Evaluate the Possible Efficacy and Safety of L- Carnitine and Sildenafil in Children Having Beta Thalassemia With Increased Tricuspid Regurgitant Jet Velocity","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-07-08","conditions":["Beta Thalassemia With Increased Tricuspid Regurgitant Jet Velocity"],"enrollment":44,"completionDate":"2024-07-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Injection, Liquid, Lotion, Solution","formulations":[{"form":"INJECTION","route":"INTRAMUSCULAR","productName":"Lipovite"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Levocarnitine"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Levocarnitine"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Carnitor"},{"form":"LIQUID","route":"ORAL","productName":"CARDIO TONIC"},{"form":"LOTION","route":"TOPICAL","productName":"IQQU Acne Serum"},{"form":"SOLUTION","route":"ORAL","productName":"Levocarnitine"},{"form":"SOLUTION","route":"ORAL","productName":"Carnitor"},{"form":"SOLUTION","route":"ORAL","productName":"Carnitor SF"},{"form":"SOLUTION","route":"ORAL","productName":"Levocarnitine"},{"form":"TABLET","route":"ORAL","productName":"Levocarnitine"},{"form":"TABLET","route":"ORAL","productName":"CARNITOR"},{"form":"TABLET","route":"ORAL","productName":"Levocarnitine"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148430","MMSL":"10540","NDDF":"000932","UNII":"0G389FZZ9M","VUID":"4020953","CHEBI":"CHEBI:16347","VANDF":"4018934","INN_ID":"6098","RXNORM":"1426681","UMLSCUI":"C0087163","chemblId":"CHEMBL1149","ChEMBL_ID":"CHEMBL1149","KEGG_DRUG":"D02176","DRUGBANK_ID":"DB00583","PDB_CHEM_ID":" 152","PUBCHEM_CID":"10917","SNOMEDCT_US":"329486002","IUPHAR_LIGAND_ID":"4780","SECONDARY_CAS_RN":"406-76-8","MESH_DESCRIPTOR_UI":"D002331"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1985-","companyName":"Sigma Tau","relationship":"Original Developer"},{"period":"present","companyName":"Leadiant Biosci Inc","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"5.0 hours","clearance":"1.6 mL/min/kg","bioavailability":"15%","fractionUnbound":"1.0%","volumeOfDistribution":"0.4 L/kg"},"publicationCount":286,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"A16AA01","allCodes":["A16AA01"]},"biosimilarFilings":[],"originalDeveloper":"Sigma Tau","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":7,"_genericFilersChecked":true,"genericManufacturerList":["Am Regent","Deva Holding As","Hikma","Novitium Pharma","Rising","Sciegen Pharms","Teva Pharms Usa"],"status":"approved","companyName":"Leadiant Biosci Inc","companyId":"leadiant-biosci-inc","modality":"Small molecule","firstApprovalDate":"1985","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1985-12-27T00:00:00.000Z","mah":"SIGMA TAU","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1985-12-27T00:00:00.000Z","mah":"SIGMA TAU","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1985-12-27T00:00:00.000Z","mah":"SIGMA TAU","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1985-12-27T00:00:00.000Z","mah":"SIGMA TAU","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1985-12-27T00:00:00.000Z","mah":"SIGMA TAU","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1985-12-27T00:00:00.000Z","mah":"SIGMA TAU","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1992-12-16T00:00:00.000Z","mah":"LEADIANT BIOSCI INC","brand_name_local":null,"application_number":"NDA020182"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2001-03-29T00:00:00.000Z","mah":"HIKMA","brand_name_local":null,"application_number":"ANDA075567"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2002-04-15T00:00:00.000Z","mah":"LEADIANT BIOSCI INC","brand_name_local":null,"application_number":"NDA019257"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-08-14T00:00:00.000Z","mah":"NOVITIUM PHARMA","brand_name_local":null,"application_number":"ANDA211676"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-12-09T00:00:00.000Z","mah":"NOVITIUM PHARMA","brand_name_local":null,"application_number":"ANDA216384"},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:35:20.787799+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}